The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic β-oxidation, and induces ketosis

The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic β-oxidation, and induces ketosis

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to increase ketone bodies in patients with type 2 diabetes; however, the underlying mechanisms have not been fully elucidated. Here we examined the effect of the SGLT2 inhibitor dapagliflozin (1 mg/kg/day, formulated in a water, PEG40...

Full description

Bibliographic Details
Main Authors: Kristina Wallenius, Tobias Kroon, Therese Hagstedt, Lars Löfgren, Maria Sörhede-Winzell, Jeremie Boucher, Daniel Lindén, Nicholas D. Oakes
Format: Article
Language:English
Published: Elsevier 2022-03-01
Series:Journal of Lipid Research
Subjects:
β-oxidation
diabetes
drug therapy
fatty acids
metabolism
tracer kinetics
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227522000098

Internet

http://www.sciencedirect.com/science/article/pii/S0022227522000098

Similar Items